OncoMatch/Clinical Trials/NCT06289751
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
Is NCT06289751 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cadonilimab and Paclitaxel-albumin for cervical cancer.
Treatment: Cadonilimab · Paclitaxel-albumin · Cisplatin — This study is an exploratory clinical trial to investigate the feasibility of neoadjuvant chemoimmunotherapy plus extrafascial hysterectomy and pelvic lymph node dissection in patients with stage IB2 (2018 FIGO) cervical cancer and to observe the response rate to treatment, adverse effects and complications, and to assess the survival rate of patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) overexpression (CPS ≥1)
Positive PD-L1 expression, Combined Positive Score (CPS) ≥1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors, including, but not limited to, other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or antibodies against immune co-stimulators (e.g., antibodies against ICOS, CD40, CD137, GITR, OX40 targets, etc.), or any other therapy targeting a mechanism of tumor immune action
Lab requirements
Blood counts
wbc ≥3.5×10^9/l, neu ≥1.5×10^9/l, plt ≥100×10^9/l
Kidney function
bun and cr ≤normal
Liver function
serum bilirubin ≤1.5 times the upper limit of normal, aminotransferase ≤1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify